Before the era of eculizumab, anti-CFH Ab-associated HUS patients were recommended for treatment with plasma exchange combined with immunosuppressive therapy [27], but the start time of plasma exchange, and the selection and course of immunosuppressive agents are still controversial. The gene discussed is CFH; the disease is hemolytic-uremic syndrome.